(Q49049736)

English

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy

scientific article published in March 2002

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Filip Van den Bosch

1

object named as

Filip Van Den Bosch

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

author name string

Elli Kruithof

2

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

Dominique Baeten

3

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

Annemie Herssens

4

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

Filip de Keyser

5

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

Herman Mielants

6

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

Eric M Veys

7

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

publication date

1 March 2002

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

46

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

3

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

755-765

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

Seronegative polyarthritis: a unified concept

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Methotrexate use in psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Identifiers

10.1002/ART.511

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/11920412

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49049736&oldid=2224352906"